Application of UGCG enzyme inhibitor in preparation of medicine for treating sepsis

By using the UGCG enzyme inhibitor Eliglustat to target the UGCG-MIF-PI3K axis, the metabolic disorders and immune disorders caused by elevated UGCG in sepsis were solved, lung damage was alleviated and organs were protected, and the mortality rate of sepsis was reduced.

CN120617518APending Publication Date: 2025-09-12PEOPLES HOSPITAL PEKING UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202510956320.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-11
Publication Date
2025-09-12

AI Technical Summary

Technical Problem

Existing technologies lack effective treatments to address sepsis, especially the metabolic disorders and immune dysregulation caused by the significant increase of UDP-glucoseceramide glucosyltransferase (UGCG) in sepsis patients, which leads to high mortality and organ damage.

Method used

UGCG enzyme inhibitors such as Eliglustat are used to inhibit UGCG enzyme activity. By targeting the UGCG-MIF-PI3K axis, they regulate cell death signals in the monocyte-macrophage cell lineage, reduce M1 macrophages, inhibit the activation of the PI3K/AKT/mTOR signaling pathway, and alleviate lung damage and systemic inflammatory responses.

Benefits of technology

Significantly prolong the survival time of patients with sepsis, reduce inflammatory infiltration of lung tissue, improve organ damage, maintain metabolic homeostasis, reduce inflammatory response and the number of M1 macrophages, and improve survival rate.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides an application of a UGCG enzyme inhibitor in preparation of a medicine for treating sepsis, and particularly relates to an application of a UGCG enzyme activity inhibitor Eliglulukast as a medicine for treating sepsis. The UGCG enzyme is remarkably increased in sepsis patients, and organ injury and systemic inflammatory response related to sepsis are effectively relieved by inhibiting the expression quantity or activity of the UGCG enzyme, influencing MIF release and inhibiting PI3K / AKT / mTOR signal channel activation, so that the survival rate of the sepsis patients is remarkably increased.
Need to check novelty before this filing date? Find Prior Art